Navigation Links
Labopharm to present at Cowen 29th Annual Health Care Conference

LAVAL, QC, March 10 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that James R. Howard-Tripp, Chief Executive Officer of the Company, will present at the Cowen and Company 29th Annual Health Care Conference at The Boston Marriott Copley Place, on Wednesday, March 18, 2009 at 11:00 a.m. ET.

Interested parties may access the live webcast for this presentation by visiting the "Events" section of the homepage of the Company's website at Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
2. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
3. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
4. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
5. Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
6. Labopharm Comments on Recent Trading Activity
7. Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
8. Labopharms NDA for Novel Trazodone Formulation accepted for review by FDA
9. Labopharm announces change to Board of Directors
10. Labopharm Reports Results for Third Quarter Fiscal 2008
11. Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... United States District Court of Connecticut on behalf of a home health care worker ... all current or former home health care workers employed by Humana, Inc., Humana at ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an ... is being more and more widely heralded as a breakthrough for performing hernia repairs. ... has over traditional laparoscopic surgery is that it can greatly reduce the pain that ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to become ... invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will ... , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health Partners, the ... Wimbledon Athletics Facebook page to educate the public, parents and school ... About 2,000 people under the age of 25 die from sudden cardiac arrest ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... Cardiac Pacemaker Market Outlook to 2019 - Rise in Cardiac ... " report to their offering. ... Boston scientific and others. --> ... Medtronic, Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology: